Buyout giants Blackstone and Carlyle are reportedly in talks about joining forces for a buyout of Swiss drugmaker Novartis’ generics unit in a deal which could be valued at about $25bn.
The post Buyout majors circle Novartis with eyes on $25bn Sandoz unit, as club deals look to make comeback first appeared on AltAssets Private Equity News.